| Title |
Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFα blocker failure
|
|---|---|
| Published in |
Biologics: Targets & Therapy, July 2012
|
| DOI | 10.2147/btt.s32244 |
| Pubmed ID | |
| Authors |
Joern Kekow, Ulf Mueller-Ladner, Hendrik Schulze-Koops |
| Abstract |
To assess the efficacy of one course of rituximab (two 1-g doses) compared to an alternative tumor necrosis factor-α (TNFα) blocker in rheumatoid arthritis patients who had experienced one previous TNFα blocker failure (eg, etanercept, adalimumab, or infliximab). |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 45 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 2% |
| Belgium | 1 | 2% |
| Unknown | 43 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 10 | 22% |
| Researcher | 9 | 20% |
| Other | 7 | 16% |
| Professor | 4 | 9% |
| Student > Postgraduate | 4 | 9% |
| Other | 7 | 16% |
| Unknown | 4 | 9% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 24 | 53% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 13% |
| Agricultural and Biological Sciences | 3 | 7% |
| Business, Management and Accounting | 1 | 2% |
| Biochemistry, Genetics and Molecular Biology | 1 | 2% |
| Other | 4 | 9% |
| Unknown | 6 | 13% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 March 2014.
All research outputs
#7,513,845
of 25,806,080 outputs
Outputs from Biologics: Targets & Therapy
#93
of 286 outputs
Outputs of similar age
#50,226
of 177,511 outputs
Outputs of similar age from Biologics: Targets & Therapy
#4
of 14 outputs
Altmetric has tracked 25,806,080 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 286 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one has gotten more attention than average, scoring higher than 66% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 177,511 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.
We're also able to compare this research output to 14 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 64% of its contemporaries.